Cargando…

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis

Background: The current study desired to conduct an economic analysis on ocrelizumab (OCR), a new relapsing multiple sclerosis (RMS) treatment strategy, in comparison to natalizumab (NTL), as one of the mostly-used disease-modifying therapies (DMTs) in Iran. Methods: A 31-health-state Markov model,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayati, Nayyereh, Taheri, Saeed, Sahraian, Mohammad Ali, Nikfar, Shekoufeh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984785/ http://dx.doi.org/10.18502/cjn.v20i3.7691

Ejemplares similares

Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

Short and long term impacts of COVID-19 on the pharmaceutical sector
por: Ayati, Nayyereh, et al.
Publicado: (2020)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2023)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
por: Garcia, Alexandra, et al.
Publicado: (2023)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis
por: Klumpp, Annika, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
por: Shahtaheri, Rahil Sadat, et al.
Publicado: (2020)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Predictors of suicidal ideation among Iranian patients with multiple sclerosis
por: Asgarian, Fatemeh Sadat, et al.
Publicado: (2020)

Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries
por: Soleymani, Fatemeh, et al.
Publicado: (2018)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
por: Kolind, Shannon, et al.
Publicado: (2023)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
por: Ho, Samantha, et al.
Publicado: (2023)

The perspective of Iranian patients with multiple sclerosis on the third dose of COVID-19 vaccine
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

Level of attitude toward complementary and alternative medicine among Iranian patients with multiple sclerosis
por: Harirchian, Mohammad Hossein, et al.
Publicado: (2014)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe
por: Aun, Marcelo Vivolo, et al.
Publicado: (2022)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Remitting Multiple Sclerosis Patients
por: Sadeghi, Hashem, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_frbh4vunes68i64vn2og9u31h6